Replies to post #9310 on Momenta Pharmaceuticals, Inc. (MNTA)

[ghmm]

I haven't looked at any preclinical papers/data (if there are even published ones). I would be curious to know the rational in the design. Pancreatic cancer has traditionally been a very hard cancer to treat the upside is that their is a very low bar/time frame to show some efficacy.

Halozyme (which I also own) has a very similar trial design underway. They started last year and I think it won't be till 2013 sometime before we have data. Their approach sounds very promising with their molecule (PEG-PH20). Don't want to go off topic on the HALO board I posted a paper and journal article link a while back if interested. I don't know if MNTA will be more aggressive in enrolling so hard to say if they'll take around the same time or longer.

There was a good seeking alpha article (rare I know) that talked about the various drugs in Pancreatic cancer (Abraxane is also one I am long via CELGZ).

[DewDiligence]

Re: Two questions re M402

Has anyone tried to handicap its chances?

Chances for commercial success? For eventually being approved? For advancing to phase-3? Please clarify your question.

What is the anticipated length of this trial phase?

Data from the first phase—i.e. the non-randomized dose-finding portion of the trial—is expected in 1H13, according to #msg-75150121. (This is also noted in #msg-76906028.)